169 related articles for article (PubMed ID: 20509261)
1. [Integrase inhibitor: raltegravir also as first line therapy].
MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
[No Abstract] [Full Text] [Related]
2. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
3. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
4. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
5. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
6. [Integrase inhibition--a new mode of action in HIV therapy].
van Lunzen J; Degen O
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
[No Abstract] [Full Text] [Related]
7. [Raltegravir: initially as effective as standard therapy].
Warpakowski A
MMW Fortschr Med; 2010 Apr; 152(17):49. PubMed ID: 20509262
[No Abstract] [Full Text] [Related]
8. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of raltegravir in HIV/AIDS.
Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir. In HIV-infected in children at least 2 years of age. Only after prior treatment failure.
Prescrire Int; 2014 Sep; 23(152):206. PubMed ID: 25325117
[TBL] [Abstract][Full Text] [Related]
11. [Raltegravir as first integrase inhibitor in an HIV-infection].
Papendorp SG; Brinkman K
Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
[No Abstract] [Full Text] [Related]
12. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
13. FDA notifications. Raltegravir indication extended for treatment-naive patients.
AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
[No Abstract] [Full Text] [Related]
14. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
15. First-line raltegravir. No evidence of comparative effectiveness.
Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
[TBL] [Abstract][Full Text] [Related]
16. Study supports use of Isentress for first line treatment.
Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560
[No Abstract] [Full Text] [Related]
17. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
18. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
[No Abstract] [Full Text] [Related]
19. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
20. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
Papendorp SG; van den Berk GE
AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
